Although, in our data, the percentage of HER2-low tumors is slightly lower compared to the female counterpart, it still remains of considerable magnitude, with approximately 35% of all MBCs classified as HER2-negative by standard analyses. Here, ERBB2 is linked to maternal uniparental disomy of chromosome 20.